奥沙利铂联合卡培他滨治疗老年进展期胃癌的临床观察

Study of oxaliplatin combined with capecitabine for advanced gastric cancer

目的观察奥沙利铂联合卡培他滨(希罗达)治疗老年晚期胃癌的有效性和安全性。方法采用奥沙利铂120mg/m2,静脉滴注2h,第1天;希罗达1000mg/m2,每天2次,第1～14天,21天为1个周期,连用2个周期后评价疗效。结果全组23例均可评价疗效,其中获得完全缓解(CR)1例(4.3%);部分缓解(PR)12例(52.1%),稳定(SD)6例(26%),进展(PD)4例(17.4%)。总有效率(CR+PR)为56.4%。不良反应主要为中性粒细胞减少、血小板减少、胃肠道反应及手足综合症等。结论奥沙利铂联合卡培他滨治疗老年晚期胃癌疗效较好,不良反应较少见,且程度轻微,值得进一步研究和应用。

Objective We evaluated the antitumour activity and toxicities of oxaliplatin and capecitabine as therapy in geriatric patients with advanced gastric cancer（AGC）.Methods Patients were treated with capecitabine 1000mg/m2 p.o.twice daily on days 1-14 and oxaliplatin 120mg/m2 i.v.on day 1 every 3 weeks until disease progression or unacceptable toxicities.Results 1 patient showed complete response and 12 showed partial response.The overall response rate 56.4%.Major toxicity was myelosuppression,enteric reaction and hand-foot syndrome.Conclusion Oxaliplatin and capecitabine combination chemotherapy is active and highly tolerable as a therapy for geriatric patients with AGC.